Wells Fargo Downgrades Bloom Energy to Equal-Weight, Lowers Price Target to $22
Wells Fargo analyst Michael Blum downgrades Bloom Energy (NYSE:BE) from Overweight to Equal-Weight and lowers the price target from $27 to $22.
Wells Fargo Downgrades The RealReal to Equal-Weight, Lowers Price Target to $2
Wells Fargo analyst Ike Boruchow downgrades The RealReal (NASDAQ:REAL) from Overweight to Equal-Weight and lowers the price target from $5 to $2.
Raymond James Downgrades Envestnet to Outperform, Raises Price Target to $71
Raymond James analyst Patrick O'Shaughnessy downgrades Envestnet (NYSE:ENV) from Strong Buy to Outperform and raises the price target from $63 to $71.
Barclays Downgrades PennyMac Financial Servs to Equal-Weight, Raises Price Target to $58
Barclays analyst Mark Devries downgrades PennyMac Financial Servs (NYSE:PFSI) from Overweight to Equal-Weight and raises the price target from $55 to $58.
Barclays Downgrades Essent Gr to Equal-Weight, Lowers Price Target to $43
Barclays analyst Mark Devries downgrades Essent Gr (NYSE:ESNT) from Overweight to Equal-Weight and lowers the price target from $54 to $43.
Wells Fargo Downgrades VF to Underweight, Announces $24 Price Target
Wells Fargo analyst Ike Boruchow downgrades VF (NYSE:VFC) from Equal-Weight to Underweight and announces $24 price target.
JP Morgan Downgrades Silvergate Capital to Neutral, Lowers Price Target to $14
JP Morgan analyst Steven Alexopoulos downgrades Silvergate Capital (NYSE:SI) from Overweight to Neutral and lowers the price target from $30 to $14.
Cowen & Co. Downgrades Fate Therapeutics to Market Perform
Cowen & Co. analyst Tyler Van Buren downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform.
Jefferies Downgrades Nuvation Bio to Hold, Lowers Price Target to $2
Jefferies analyst Michael Yee downgrades Nuvation Bio (NYSE:NUVB) from Buy to Hold and lowers the price target from $5 to $2.
Deutsche Bank Downgrades Bank of America to Hold, Lowers Price Target to $36
Deutsche Bank analyst Matt O'Connor downgrades Bank of America (NYSE:BAC) from Buy to Hold and lowers the price target from $45 to $36.